# Nanomedicine and the EPR effect

> A figure of how nanomedicines reach a tumour. A 3D cutaway contrasts a normal vessel — tight junctions, draining lymphatics — with a leaky tumour vessel whose endothelial gaps let nanoparticles out, and whose collapsed lymphatics keep them in: the enhanced permeability and retention (EPR) effect. A PEGylated carrier and a 2D tumour scene show the reality — limited penetration and uptake by macrophages — and the delivery efficiency actually measured.

- Page: https://www.labcanvas.com/templates/cancer-biology/nanomedicine-epr-effect
- Open in the LabCanvas editor (LabCanvas account): https://www.labcanvas.com/editor.html?template=nanomedicine-epr-effect
- Updated: 2026-10-14
- Category: Cancer biology
- Method: Graphical abstract
- Product: How nanoparticle carriers accumulate in a tumour, and why delivery is inefficient
- Key result: Tumour-vessel pore cutoff ~0.2–1.2 µm; a median of ~0.7% of the injected nanoparticle dose reaches solid tumours in published animal studies (Wilhelm et al. 2016)
- Figure: 1920 × 1080 px, 29 editable layers (2 generated objects with settings)

## Steps

1. **Normal vessel**: Tight junctions between endothelial cells keep nanoparticles in the blood; lymphatics drain fluid and particles away (Jain & Stylianopoulos 2010)
2. **The EPR effect**: Leaky tumour vessels have gaps between endothelial cells (pore cutoff ~0.2–1.2 µm) that let nanoparticles out; collapsed lymphatics keep them there (Maeda et al. 2000)
3. **The carrier**: A ~100 nm carrier with a PEG corona circulates long enough to reach the tumour; ligands can add active targeting
4. **The reality**: Penetration into dense matrix is limited and tumour-associated macrophages take up much of the dose; a median of only ~0.7% of the injected dose reaches the tumour (Wilhelm et al. 2016)

## Uses

- Nanomedicine review and graphical-abstract figures
- Drug-delivery talks and posters
- Teaching passive targeting and its limits

## References

1. Maeda et al., “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review”, J. Control. Release 2000. https://doi.org/10.1016/S0168-3659(99)00248-5 (method origin)
2. Jain & Stylianopoulos, “Delivering nanomedicine to solid tumors”, Nat. Rev. Clin. Oncol. 2010. https://doi.org/10.1038/nrclinonc.2010.139 (review)
3. Wilhelm et al., “Analysis of nanoparticle delivery to tumours”, Nat. Rev. Mater. 2016. https://doi.org/10.1038/natrevmats.2016.14 (primary)

Credit: Drawn in LabCanvas after Maeda et al., J. Control. Release 2000 (doi:10.1016/S0168-3659(99)00248-5); Jain & Stylianopoulos, Nat. Rev. Clin. Oncol. 2010 (doi:10.1038/nrclinonc.2010.139); and Wilhelm et al., Nat. Rev. Mater. 2016 (doi:10.1038/natrevmats.2016.14). Schematic, not to scale.

## Questions

**What does the “Nanomedicine and the EPR effect” template show?** A figure of how nanomedicines reach a tumour. A 3D cutaway contrasts a normal vessel — tight junctions, draining lymphatics — with a leaky tumour vessel whose endothelial gaps let nanoparticles out, and whose collapsed lymphatics keep them in: the enhanced permeability and retention (EPR) effect. A PEGylated carrier and a 2D tumour scene show the reality — limited penetration and uptake by macrophages — and the delivery efficiency actually measured.

**What are the steps shown in “Nanomedicine and the EPR effect”?** 1. Normal vessel: Tight junctions between endothelial cells keep nanoparticles in the blood; lymphatics drain fluid and particles away (Jain & Stylianopoulos 2010). 2. The EPR effect: Leaky tumour vessels have gaps between endothelial cells (pore cutoff ~0.2–1.2 µm) that let nanoparticles out; collapsed lymphatics keep them there (Maeda et al. 2000). 3. The carrier: A ~100 nm carrier with a PEG corona circulates long enough to reach the tumour; ligands can add active targeting. 4. The reality: Penetration into dense matrix is limited and tumour-associated macrophages take up much of the dose; a median of only ~0.7% of the injected dose reaches the tumour (Wilhelm et al. 2016).

**Which papers is “Nanomedicine and the EPR effect” based on?** Maeda et al., “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review”, J. Control. Release 2000 (doi:10.1016/S0168-3659(99)00248-5); Jain & Stylianopoulos, “Delivering nanomedicine to solid tumors”, Nat. Rev. Clin. Oncol. 2010 (doi:10.1038/nrclinonc.2010.139); Wilhelm et al., “Analysis of nanoparticle delivery to tumours”, Nat. Rev. Mater. 2016 (doi:10.1038/natrevmats.2016.14).

**Can I edit the “Nanomedicine and the EPR effect” template?** Yes. Open it in the LabCanvas editor: all 29 layers are editable, including 2 generated objects (structures, plots, equipment) with their own settings. Change the text, colours and layout, then export PNG, TIFF or PDF at the width and DPI the journal asks for.

**Do I need an account to use this template?** Not to view it here. To open and edit it, sign in to LabCanvas or create a free account (the free plan keeps up to 3 designs). Downloading the figure is part of LabCanvas Pro (US$19 a month or US$199 a year).
